FMNL1: A Protein Implicated in Pregnancy and Many Diseases (G752)

Target Name: FMNL1

NCBI ID: G752

FMNL1

FMNL1: A Protein Implicated in Pregnancy and Many Diseases

FMNL1 (FMN1) is a protein that is expressed in the human placenta and has been shown to play a role in the development and maintenance of pregnancy. The full name of the protein is fenylmethionine-containing loop 1, and it is also known as FMNL.

FMNL1 is a member of the FMN1 gene family, which is known for producing fenylmethionine-containing proteins. This gene family has also been implicated in the development and progression of many diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

FMNL1 has been shown to be involved in the regulation of cell proliferation and survival, as well as in the development of the placenta. It has been shown to play a role in the formation of blood vessels in the placenta, which is important for the supply of oxygen and nutrients to the developing fetus.

In addition to its role in the placenta, FMNL1 has also been shown to be involved in the regulation of other cell processes, including cell adhesion, migration, and invasion. It has been shown to interact with a variety of different proteins, including the transcription factor PDGF-BB and the protein tyrosine kinase FAK.

Despite its potential involvement in many different cellular processes, little is currently known about the specific functions of FMNL1. However, studies suggest that FMNL1 may be a drug target or biomarker for a variety of different diseases.

One potential drug target for FMNL1 is cancer. FMNL1 has been shown to be involved in the regulation of cell proliferation and survival, which are often associated with the development of cancer. Therefore, inhibiting the activity of FMNL1 may be a promising approach for the treatment of cancer.

Another potential drug target for FMNL1 is neurodegenerative disorders. FMNL1 has been shown to play a role in the regulation of cell survival and proliferation, which may be involved in the development and progression of neurodegenerative disorders. Therefore, targeting the activity of FMNL1 with drugs that can promote cell death or inhibit cell proliferation may be a promising approach for the treatment of neurodegenerative disorders.

FMNL1 may also be a biomarker for some diseases. FMNL1 has been shown to be expressed in the placenta, which is a potential indicator of the health of the developing fetus. Therefore, measuring the level of FMNL1 in the placenta may be a useful biomarker for the diagnosis and monitoring of fetal health.

In conclusion, FMNL1 is a protein that has been shown to play a role in the development and maintenance of pregnancy, as well as in the regulation of many different cellular processes. While more research is needed to fully understand the functions of FMNL1, it may be a promising drug target or biomarker for the treatment of cancer, neurodegenerative disorders, and other diseases.

Protein Name: Formin Like 1

Functions: May play a role in the control of cell motility and survival of macrophages (By similarity). Plays a role in the regulation of cell morphology and cytoskeletal organization. Required in the cortical actin filament dynamics and cell shape

The "FMNL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FMNL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets